ArticleCancers2022
Multidisciplinary Tumor Board in the Management of Patients with Colorectal Liver Metastases: A Single-Center Review of 847 Patients.
Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- The Role of Radiologists in Multidisciplinary Tumor Boards for Colorectal Cancer with Liver Metastases: a Systematic Review.Current oncology reports · 2025Pooled it
- Tele-Expert Consultation for Locally Recurrent Rectal Cancer: A Prospective Multicenter Evaluation of the CONNECT-LR System.Annals of surgical oncology · 2026Observational
- Optimizing Precision Oncology: Structural Frameworks for Local MTB Integration and Outcome Assessment.Medical sciences (Basel, Switzerland) · 2026Review
- Comparison of artificial intelligence and multidisciplinary team recommendations in the management of colorectal cancer liver metastases.Scientific reports · 2026Article
- How to Integrate Surgery into the Multidisciplinary Treatment of Liver-Only Metastatic Colorectal Cancer.Cancers · 2026Review
- Survival of hepatectomy in colorectal cancer patients with ten or more liver metastases: a retrospective cohort study of multidisciplinary treatment.Journal of gastrointestinal oncology · 2025Article
- Article
- Adherence to Multidisciplinary Tumor Board Recommendations and Its Association with Survival: A Retrospective Observational Study of Colorectal Cancer Patients.Journal of gastrointestinal cancer · 2025Observational
- Causative Genes of Homologous Recombination Deficiency (HRD)-Related Breast Cancer and Specific Strategies at Present.Current oncology (Toronto, Ont.) · 2025Review
- Assessing the Impact of Multidisciplinary Team (MDT) Care on Patients with Liver Cancer/Cirrhosis: A Systematic Review and Meta-Analysis.Iranian journal of public health · 2025Review
- Preoperative imaging of colorectal liver metastases: what the radiologist and the multidisciplinary team need to know.The British journal of radiology · 2024Review
- Current landscape of preoperative neoadjuvant therapies for initial resectable colorectal cancer liver metastasis.World journal of gastroenterology · 2024Review
- Article
- Liver Transplantation for Hepatic Metastases from Colorectal Cancer: Current Knowledge and Open Issues.Cancers · 2023Review
- Cloud platform to improve efficiency and coverage of asynchronous multidisciplinary team meetings for patients with digestive tract cancer.Frontiers in oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is still debate over how reviewing oncological histories and addressing appropriate therapies in multidisciplinary team (MDT) discussions may affect patients’ overall survival (OS). The aim of this study was to describe MDT outcomes for a single cancer center’s patients affected by colorectal liver metastases (CRLMs). From 2010 to 2020, a total of 847 patients with CRLMs were discussed at our weekly MDT meeting. Patients’ characteristics and MDT decisions were analyzed in two groups: patients receiving systemic therapy (ST) versus patients receiving locoregional treatment (LRT). Propensity-score matching (PSM) was run to reduce the risk of selection bias. The median time from MDT indication to treatment was 27 (IQR 13−51) days. The median OS was 30 (95%CI = 27−34) months. After PSM, OS for patients undergoing LRT was 51 (95%CI = 36−64) months compared with 15 (95%CI = 13−20) months for ST patients (p < 0.0001). In this large retrospective study, the MDT discussions were useful in providing the patients with all available locoregional options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.